A revolutionary biomolecule construction platform where quantum computing and artificial intelligence converge in a closed wet lab loop. This integrated system accelerates discovery, validation, and deployment across five critical verticals—therapeutics, diagnostics, biomanufacturing, agritech, and biological control systems. By unifying computational power with experimental biology through in vitro and in vivo validation platforms, the technology compresses decades of traditional R&D into months with minimal failure rates.
Accelerating Drug Discovery
Drug discovery is running out of room. Nearly all approved biotherapeutics originate from the same 2% of the genome — the protein-coding regions every major pharma company has already mined for two decades.
Scientifically, most "easy" targets are already drugged. Small molecules generally need a well-defined binding pocket to work, but an estimated 80% of the human proteome is considered undruggable by that approach — proteins with flat surfaces, disordered regions, or protein-protein interactions that a small molecule simply can't grip.
The result is a pipeline crisis: rising R&D costs, shrinking hit rates, and a wave of "innovation" that is really just generics and combinations of existing drugs. Meanwhile the disease burden keeps growing — cancer, antimicrobial resistance, malaria, and dementia alone represent tens of millions of new cases and hundreds of billions in annual spend, with no proportional increase in genuinely novel chemistry to meet it.
Quantum-Powered Molecular Design
Quantum algorithms simulate protein folding and drug-target interactions with unprecedented accuracy, exploring billions of molecular configurations simultaneously.
AI models trained on experimental feedback predict binding affinity and therapeutic efficacy before synthesis.
Quantum Codon's platform opens a different part of the genome entirely: the 98% that was long dismissed as "junk DNA." Our founding research team has spent over fifteen years building the scientific case, published peer-reviewed papers, to demonstrate that the dark matter of genome — intergenic DNA, antisense strands, reverse ORFs, pseudogenes, introns, rRNA, tRNA, and lncRNA — is an untapped reservoir of biological assets that evolution probably never used .
Platform Architecture: Closing the Loop
Wet lab results feed directly back into quantum-AI models, refining predictions in real-time. In vitro screening validates lead compounds within weeks, while in vivo models confirm safety and efficacy—compressing traditional timelines to faster deliverables.
Quantum Computing
Molecular simulations, pathway optimization, complex system modeling at scales impossible for classical computers.
AI/ML Models
Predictive algorithms, experimental design optimization, pattern recognition across multi-dimensional datasets.
Wet Lab Automation
High-throughput in vitro screening, robotic liquid handling, automated data collection and integration.
In Vivo Validation
Disease models, efficacy testing, safety assessment in living systems—confirming computational predictions.
Feedback Integration
Experimental results continuously refine quantum-AI models, creating ever-more accurate predictive capabilities.
This closed-loop architecture eliminates traditional handoffs between computational and experimental teams. Data flows seamlessly from quantum simulations through AI predictions to wet lab validation and back—creating a self-improving system that accelerates with each iteration cycle. The result: 5-10× faster development timelines across all verticals.
Using computational prediction and experimental validation, we convert this dark genomic space into first-in-class molecules with clean, defensible assets with no prior art
This is not a hypothesis: our platform has already generated validated candidates with demonstrated activity against cancer, malaria, leishmaniasis, Alzheimer's disease, and drug-resistant pathogens, including tRNA-encoded peptides (tREPs), a molecular class we discovered and named. Our lead compound, tREP-18, showed potent antileishmanial activity at nanomolar concentrations (IC₅₀ ≈ 22 nM) while sparing human cells — proof that this approach can produce not just novel molecules, but drug-like ones.
For investors, this means a proprietary discovery engine sitting on genomic real estate no competitor has staked a claim to — a pipeline of first-in-class assets generated at a fraction of the cost and timeline of conventional discovery, with a founding team whose published track record de-risks the science years ahead of typical seed-stage platforms.
Our anticancer, antimalarial and wound healing molecules have passed the animal testing. The innovation pipeline is long. Fifteen years of foundational science. A validated discovery pipeline. A part of the genome no one else has touched. This is the Quantum Codon platform.
For industry partners, this means access to pre-validated, screened molecules and enzyme candidates ready for licensing or tech transfer — new chemical entities and catalytic scaffolds that expand your pipeline without inheriting the freedom-to-operate constraints of conventionally sourced IP.
Publications
Preprints_org
Recoding Genomic Elements with AI and Quantum Computation to Build the Next Generation Drug Discovery Platform
The traditional view of the genome has largely centered on protein-coding and non-coding regions, as these parts show clear observable functions. The non-coding sequences previously considered “junk DNA” have been extensively studied for the last few decades and are recognized to encode regulatory elements. This shift is expanding our understanding of genome complexity and its hidden potential. The non expressing sequences have not received much attention. To our best knowledge, we demonstrated
2026: Nayak S, M.Garg, UMR Chanchala, SK Saxena, Pk Dhar. The Unread Genome: Decoding Biology’s Dark Matter, In "BioRevolution: From genes to global solutions” Manfred J Kern, Kunal, Machiavelli Singh Eds. Agrobios Research 2026, pp 53-71. ISBNs: 978-93-49045-87-3
2025 : Krishnan K, A Chugh, V Niranja, PK Dhar. Recoding Genomic Elements with AI and Quantum Computation to Build the Next Generation Drug Discovery Platform. Preprints https://www.preprints.org/manuscript/202505.1422
2023: Verma, N., Manvati, S., & Dhar, P. K. Harnessing Escherichia coli’s Dark Genome to Produce Anti-Alzheimer Peptides. BioRxiv. https://doi.org/10.1101/2023.06.23.546343
2023: Garg, M., & Dhar, P. K. Repurposing the Dark Genome I: Antisense Proteins. bioRxiv. https://doi.org/10.1101/2023.03.15.532699
2023: Nayak, S., & Dhar, P. K. Repurposing the Dark Genome II – _Reverse Proteins. bioRxiv. https://doi.org/10.1101/2023.03.20.533367
2023: Garg, M., & Dhar, P. K. Repurposing The Dark Genome. III - Intronic Proteins. bioRxiv. https://doi.org/10.1101/2023.06.10.544447
2023: Nayak, S., & Dhar, P. K. Repurposing the Dark Genome IV – _Noncoding Proteins. bioRxiv. https://doi.org/10.1101/2023.06.29.547021
2022: Chakrabarti, A., Kaushik, M., Khan, J., et al. tREPs – _a new class of functional tRNA encoded peptides. ACS Omega, 2022: 7(22), 18361–18373. https://doi.org/10.1021/acsomega.2c01234
2017: Varughese, D., Nair, A. S., & Dhar, P. K. Function annotation of novel peptides generated from the non-expressing genome of Drosophila melanogaster. Bioinformation, 13(1), 17–20.
2015: Krishnan, R., Kumar, V., Ananth, V., et al. Computational identification of novel microRNAs and their targets in the malarial vector Anopheles stephensi. Systems and Synthetic Biology Journal, 9, 11–17.
2015: Raj, N., Helen, A., Manoj, N., et al. In silico study of peptide inhibitors against BACE. Systems and Synthetic Biology Journal, 9, 67–72.
2015: Shidhi, P. R., Suravajhala, P., Nayeema, A., et al. Making novel proteins from pseudogenes. Bioinformatics, 31(1), 33–39. https://doi.org/10.1093/bioinformatics/btu585
2013: Joshi, M., Kundapura, S. V., Poovaiah, T., Ingle, K., & Dhar, P. K. Discovering novel anti-malarial peptides from the not-coding genome—A working hypothesis. Current Synthetic and Systems Biology, 1(1).
2009. Dhar, P. K., Nanduri, B., et al. Synthesizing non-natural parts from natural genomic template. Journal of Biological Engineering, 2009: 3, 2. https://doi.org/10.1186/1754-1611-3-2
The Future of Biotherapeutics has arrived!